Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/11/2020
SIETES contiene 93161 citas

 
 
<< anterior 21 a 40 de 290 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas Cita con resumen
Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB, ESA Clinic Study Group. Impact of pharmacist-managed erythropoiesis - Stimulating agents clinics for patients with non-dialysis-dependent CKD. Am J Kidney Dis 2012;60:371-9. [Ref.ID 92943]
22.Tiene citas relacionadas Cita con resumen
Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012;60:390-41. [Ref.ID 92942]
23. Cita con resumen
Montastruc J-L. Médicaments déterminant HTA : du nouveau !. BIP31.fr 2012;19:19-20. [Ref.ID 92664]
24. Cita con resumen
Anónimo. FDA approves peginesatide for anemia. DIA Daily 2012:28 de marzo. [Ref.ID 92479]
26.
Ebbers HC, Mantel-Teeuwisse AK, Moors EHM, Schellekens H, Leufkens HG. Today's challenges in pharmacovigilance: what can we learn from epoetins?. Drug Saf 2011;34:273-87. [Ref.ID 90434]
27. Cita con resumen
Bennett CL, Lai SY, Henke M, Barnato SE, Armitage JO, Sartor O. Association betweeen pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med 2010;170:1490-8. [Ref.ID 89349]
28. Cita con resumen
Frau S, Font Pous M, Luppino MR, Conforti A. Risk management plans: are they a tool for improving drug safety?. Eur J Clin Pharmacol 2010;66:785-90. [Ref.ID 89061]
29.Tiene citas relacionadas
Weiner DE, Miskulin DC. Anemia management in chronic kidney disease: bursting the hemogloblin bubble. Ann Intern Med 2010;153:53-4. [Ref.ID 88834]
30.Tiene citas relacionadas Cita con resumen
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GFM. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153:23-33. [Ref.ID 88832]
31.Tiene citas relacionadas Cita con resumen
Unger EF, Thompson AM, Temple R. Reevaluating erythropoiesis-stimulating agents. The authors reply. N Engl J Med 2010;362:1743-4. [Ref.ID 88475]
32.Tiene citas relacionadas Cita con resumen
Cotter DJ. Reevaluating erythropoiesis-stimulating agents. N Engl J Med 2010;362:1743. [Ref.ID 88474]
33.Tiene citas relacionadas Cita con resumen
Kimmel PL, Malozowski S. Reevaluating erythropoiesis-stimulating agents. N Engl J Med 2010;362:1742-3. [Ref.ID 88473]
34.Tiene citas relacionadas Cita con resumen
Kestenbaum B. Reevaluating erythropoiesis-stimulating agents. N Engl J Med 2010;362:1742-3. [Ref.ID 88472]
35. Cita con resumen
Laporte JR. Pour une pharmacovigilance plus ambitieuse. Prescrire 2010;30:391-3. [Ref.ID 88457]
36. Cita con resumen
Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nature Biotechnology 2010;28:28-31. [Ref.ID 88169]
37. Cita con resumen
38.
Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010;303:857-64. [Ref.ID 87978]
39.Tiene citas relacionadas
Pfeffer MA, Eckardt K-U, Toto R. Darbepoetin alfa and chronic kidney disease. The authors reply. N Engl J Med 2010;362:655. [Ref.ID 87900]
40.Tiene citas relacionadas
Locatelli F, Del Vecchio L, Casartelli D. Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010;362:654-5. [Ref.ID 87899]
Seleccionar todas
 
<< anterior 21 a 40 de 290 siguiente >>